<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542161</url>
  </required_header>
  <id_info>
    <org_study_id>20-01021280</org_study_id>
    <secondary_id>R01NS116887</secondary_id>
    <nct_id>NCT04542161</nct_id>
  </id_info>
  <brief_title>Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</brief_title>
  <acronym>NAC ME/CFS</acronym>
  <official_title>Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained&#xD;
      multisymptom/multisystem disorder for which there are currently no validated treatments. The&#xD;
      present exploratory clinical trial aims to advance our understand of the mechanisms of in&#xD;
      situ GSH synthesis control through assessment of the response of brain GSH and plasma markers&#xD;
      of oxidative stress to different doses of NAC in comparison to placebo, as a potential&#xD;
      treatment for ME/CFS that would provide neuroprotection against oxidative stress by restoring&#xD;
      cortical GSH reserves. If successful, this exploratory clinical trial would address a&#xD;
      significant public health concern by shedding new light onto the mechanisms of action of NAC&#xD;
      in brain GSH restoration, which could open a new avenue for the development of potentially&#xD;
      effective treatments for a disorder, ME/CFS, that currently has none.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase two, single-site study will utilize a double-blind, placebo-controlled,&#xD;
      randomized, pre-/post-treatment design to investigate the effect of NAC dosing on brain GSH&#xD;
      levels and measure temporally concordant plasma levels of several established circulating&#xD;
      markers of oxidative stress. Three study groups, of 20 subjects each (for a total of 60 who&#xD;
      completed all components of the study), will each be administered a different dose (0 mg/day,&#xD;
      900mg/day, 3600mg/day) of the study intervention over a four week period; N-acetylcysteine&#xD;
      (NAC) treatment. Subjects receiving 0 mg/day dose will be administered a placebo. Baseline&#xD;
      visit assessments will include blood collection, survey questionnaires, MRI and MRS imaging.&#xD;
      Subjects whose initial screening confirms low GSH level at baseline will be provided with a&#xD;
      4-week supplement of anonymized NAC or placebo caplets. After 4 weeks, subjects will then&#xD;
      undergo a follow-up visit to repeat the baseline assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GSH levels of treatment response</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Levels of striatal and occipital cortex GSH, as measured in vivo with 1H MRS,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response: measure 1</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of F2-isoprostanes, a marker of oxidative stress, in plasma samples obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of levels of ventricular CSF lactate of treatment response</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Levels of ventricular CSF lactate, as measured in vivo with 1H MRS,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of regional cerebral blood flow (rCBF) of treatment response</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Regional cerebral blood flow (rCBF), as measured in vivo with perfusion MRI,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response:measure 2</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of 8-hydroxy-2-deoxy guanosine (8-OH-2dG), a DNA damage marker, in plasma samples obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response:measure 3</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of reduced (GSH) glutathione, an antioxidant capacity and redox state marker, in plasma obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response:measure 4</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of oxidized (GSSG) glutathione, an antioxidant capacity and redox state marker, in plasma obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response:measure 5</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of GSH peroxidase, an antioxidant enzyme activity marker, in plasma obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative stress levels of treatment response:measure 6</measure>
    <time_frame>pre/post 4 weeks of NAC supplementation</time_frame>
    <description>Level of protein carbonyls, a protein damage marker, in plasma obtained</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Myalgic Encephalomyelitis</condition>
  <arm_group>
    <arm_group_label>NAC 900mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAC 3600mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAC 0mg/day (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC 900mg/day</intervention_name>
    <description>self administer NAC 900mg/day caplets for a four week period</description>
    <arm_group_label>NAC 900mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC 3600mg/day</intervention_name>
    <description>self administer NAC 3600mg/day caplets for a four week period</description>
    <arm_group_label>NAC 3600mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC 0mg/day (Placebo)</intervention_name>
    <description>self administer NAC 0mg/day (placebo) caplets for a four week period</description>
    <arm_group_label>NAC 0mg/day (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, ages 21 to 60 years (inclusive).&#xD;
&#xD;
          -  Baseline GSH levels at or less than a predefined cutoff value.&#xD;
&#xD;
          -  Primary diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).&#xD;
&#xD;
          -  Willing and capable of providing informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant and/or comorbid axis I (especially mood and anxiety) and axis II&#xD;
             disorders.&#xD;
&#xD;
          -  Any significant neurological illness or impairment.&#xD;
&#xD;
          -  Other unstable medical conditions (asthma, hypertension, endocrine or metabolic&#xD;
             disease, etc).&#xD;
&#xD;
          -  History alcohol abuse.&#xD;
&#xD;
          -  Positive urine toxicology at screening and on days of assessments.&#xD;
&#xD;
          -  Positive pregnancy test at screening or on days of assessments.&#xD;
&#xD;
          -  Contra-indication for clinical MRI scan (e.g., pacemaker, metallic prosthesis).&#xD;
&#xD;
          -  Baseline GSH levels higher than a predefined cutoff value.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dikoma Shungu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihyun Lee, MPH</last_name>
    <phone>2127462481</phone>
    <email>jil4015@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangling Mao, MS</last_name>
    <phone>2127462632</phone>
    <email>xim2004@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dikoma C. Shungu, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiangling Mao, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Sweeney, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

